Business
Viatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance
Viatris to host its inaugural virtual Investor Day on March 1, 2021, as previously announced PITTSBURGH, Feb. 9, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ:
About this update from Viatris Inc.
[{"type":"text","content":"Viatris to host its inaugural virtual Investor Day on March 1, 2021, as previously announced\n\n\nPITTSBURGH, Feb. 9, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that it will host a conference call at 8 a.m. ET on Monday, Feb. 22 to discuss 2021 financial guidance.\nThe briefing can be accessed live by calling (855) 493-3607 or (346) 354-0950 for international callers (ID#: 3235536) or at the following address on the company's website: investor.viatris.com. A slide presentation and replay of the webcast also will be available on the website. \nAs previously announced, Viatris will hold its inaugural Investor Day virtually on Monday, March 1, 2021. The event will begin at 8:30 a.m. ET. CEO Michael Goettler, President Rajiv Malik, Chief Financial Officer Sanjeev Narula and several other members of the leadership team will present a deep dive into the company's strategy to optimize total shareholder return, while delivering on its mission to empower people worldwide to live healthier at every stage of life. \nInterested parties will be able to access a live webcast of the Investor Day event via the investor relations section of Viatris' website at investor.viatris.com. A replay and archived edition of the presentation will be available following the event.\nAbout Viatris Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,0...